Marta Szajnik1, Magdalena Derbis2, Michal Lach2, Paulina Patalas2, Marcin Michalak3, Hanna Drzewiecka4, Dariusz Szpurek5, Andrzej Nowakowski6, Marek Spaczynski3, Włodzimierz Baranowski6, Theresa L Whiteside7. 1. Departments of Gynecology Oncology, Military Institute of Medicine, Warsaw, Poland ; Department of Gynecology and Gynecologic Oncology, Military Institute of Medicine, Warsaw, Poland. 2. Department of Clinical Immunology Military Institute of Medicine, Warsaw, Poland. 3. Departments of Gynecology Oncology, Military Institute of Medicine, Warsaw, Poland. 4. Department of Biochemistry and Molecular Biology, Military Institute of Medicine, Warsaw, Poland. 5. Division of Gynecology Surgery, Poznan University of Medical Sciences, 61-701 Poznan, Poland. 6. Department of Gynecology and Gynecologic Oncology, Military Institute of Medicine, Warsaw, Poland. 7. University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA.
Abstract
BACKGROUND: In patients with Ovarian Cancer (OvCa) exosomes released by tumor cells are present in the plasma and could be involved in tumor progression. This study examines the association between the exosome presence/protein content in plasma of OvCa patients and disease outcome, response to standard therapy and/or tumorresistance to therapies in patients studied at diagnosis and also serially during and after therapy. DESIGN AND METHODS: Exosomes were purified from OvCa patients' plasma (n=22), patients with benign tumors (n=10) or (n=10) healthy controls (NC) using ultracentrifugation. Exosomes were visualized by scanning electron microscopy. Their protein content was measured. The presence of MAGE 3/6 and TGF-β1 in exosomes was evaluated in Western blots. RESULTS: The OvCa patients' plasma contained higher levels of exosomal proteins (p<0.05) compared to those isolated from plasma of patients with benign tumors or NC. Exosomes isolated from OvCa patients's plasma carried TGF-β1 and MAGE3/6, which distinguished OvCa patients from those with benign tumors and NC. High protein levels of exosomes were seen in newly diagnosed patients; however in advanced stages of OvCa patients the protein content of isolated exosomes was significantly higher than that of early stages. The exosome levels variably changed during/after chemotherapy, and correlations between the changes in exosomal protein levels and clinical data suggested that the protein content of exosomes might be useful in predicting responses to therapy and prognosis in OvCa patients. CONCLUSION: Analysis of plasma exosomes levels offers a novel approach to diagnosis and monitoring response to therapies in OvCa patients.
BACKGROUND: In patients with Ovarian Cancer (OvCa) exosomes released by tumor cells are present in the plasma and could be involved in tumor progression. This study examines the association between the exosome presence/protein content in plasma of OvCa patients and disease outcome, response to standard therapy and/or tumorresistance to therapies in patients studied at diagnosis and also serially during and after therapy. DESIGN AND METHODS: Exosomes were purified from OvCa patients' plasma (n=22), patients with benign tumors (n=10) or (n=10) healthy controls (NC) using ultracentrifugation. Exosomes were visualized by scanning electron microscopy. Their protein content was measured. The presence of MAGE 3/6 and TGF-β1 in exosomes was evaluated in Western blots. RESULTS: The OvCa patients' plasma contained higher levels of exosomal proteins (p<0.05) compared to those isolated from plasma of patients with benign tumors or NC. Exosomes isolated from OvCa patients's plasma carried TGF-β1 and MAGE3/6, which distinguished OvCa patients from those with benign tumors and NC. High protein levels of exosomes were seen in newly diagnosed patients; however in advanced stages of OvCa patients the protein content of isolated exosomes was significantly higher than that of early stages. The exosome levels variably changed during/after chemotherapy, and correlations between the changes in exosomal protein levels and clinical data suggested that the protein content of exosomes might be useful in predicting responses to therapy and prognosis in OvCa patients. CONCLUSION: Analysis of plasma exosomes levels offers a novel approach to diagnosis and monitoring response to therapies in OvCa patients.
Entities:
Keywords:
Exosomes; Ovarian carcinoma; Prognosis; Response to therapy
Authors: Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa-Silva; Gema Moreno-Bueno; Marta Hergueta-Redondo; Caitlin Williams; Guillermo García-Santos; Cyrus Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A Garcia; Margaret K Callahan; Jianda Yuan; Vilma R Martins; Johan Skog; Rosandra N Kaplan; Mary S Brady; Jedd D Wolchok; Paul B Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden Journal: Nat Med Date: 2012-06 Impact factor: 53.440
Authors: Michael G Kelly; Ayesha B Alvero; Rui Chen; Dan-Arin Silasi; Vikki M Abrahams; Serena Chan; Irene Visintin; Thomas Rutherford; Gil Mor Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: Salma Khan; Jessica M S Jutzy; Malyn May A Valenzuela; David Turay; Jonathan R Aspe; Arjun Ashok; Saied Mirshahidi; Dan Mercola; Michael B Lilly; Nathan R Wall Journal: PLoS One Date: 2012-10-16 Impact factor: 3.240
Authors: Aaron H Morris; Sophia M Orbach; Grace G Bushnell; Robert S Oakes; Jacqueline S Jeruss; Lonnie D Shea Journal: Cancer Res Date: 2020-05-14 Impact factor: 12.701
Authors: Gautam N Shenoy; Maulasri Bhatta; Jenni L Loyall; Raymond J Kelleher; Joel M Bernstein; Richard B Bankert Journal: Immunol Invest Date: 2020-04-17 Impact factor: 3.657